Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)
13.00 x 10 24.00 x 51
Post-market by (Cboe BZX)
18.94 +0.64 (+3.50%) 04/21/25 [NASDAQ]
13.00 x 10 24.00 x 51
Post-market 18.94 unch (unch) 16:01 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
17.99
Day High
19.30
Open 18.07
Previous Close 18.30 18.30
Volume 609,300 609,300
Avg Vol 898,440 898,440
Stochastic %K 78.68% 78.68%
Weighted Alpha -49.58 -49.58
5-Day Change +2.10 (+12.47%) +2.10 (+12.47%)
52-Week Range 14.40 - 47.00 14.40 - 47.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,214,827
  • Shares Outstanding, K 66,384
  • Annual Sales, $ 7,020 K
  • Annual Income, $ -157,860 K
  • EBIT $ -195 M
  • EBITDA $ -208 M
  • 60-Month Beta 1.59
  • Price/Sales 168.32
  • Price/Cash Flow N/A
  • Price/Book 1.58

Options Overview Details

View History
  • Implied Volatility 88.35% ( +17.04%)
  • Historical Volatility 68.66%
  • IV Percentile 84%
  • IV Rank 47.08%
  • IV High 141.27% on 04/11/25
  • IV Low 41.26% on 06/24/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 60
  • Volume Avg (30-Day) 252
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 5,747
  • Open Int (30-Day) 5,880

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.75
  • Number of Estimates 6
  • High Estimate -0.65
  • Low Estimate -0.88
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -33.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.40 +31.53%
on 04/09/25
Period Open: 19.64
21.01 -9.87%
on 03/25/25
-0.70 (-3.56%)
since 03/21/25
3-Month
14.40 +31.53%
on 04/09/25
Period Open: 24.61
26.26 -27.88%
on 01/30/25
-5.67 (-23.04%)
since 01/21/25
52-Week
14.40 +31.53%
on 04/09/25
Period Open: 37.98
47.00 -59.70%
on 09/25/24
-19.04 (-50.13%)
since 04/19/24

Most Recent Stories

More News
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeutics  (NASDAQ:...

AGIO : 27.34 (-1.16%)
CLDX : 18.94 (+3.50%)
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeutics  (NASDAQ:...

AGIO : 27.34 (-1.16%)
CLDX : 18.94 (+3.50%)
Celldex Therapeutics to Present at Upcoming Investor Conferences

CLDX : 18.94 (+3.50%)
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

CLDX : 18.94 (+3.50%)
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

CLDX : 18.94 (+3.50%)
Celldex: Q4 Earnings Snapshot

Celldex: Q4 Earnings Snapshot

CLDX : 18.94 (+3.50%)
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

CLDX : 18.94 (+3.50%)
Celldex Therapeutics Initiates Phase 2 Study of Barzolvolimab for Atopic Dermatitis Treatment

Celldex Therapeutics initiates Phase 2 study of barzolvolimab for treating atopic dermatitis, currently enrolling patients.Quiver AI SummaryCelldex Therapeutics has launched a Phase 2 study of its monoclonal...

CLDX : 18.94 (+3.50%)
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

CLDX : 18.94 (+3.50%)
Celldex Therapeutics Initiates Phase 1a Trial for Bispecific Antibody CDX-622 Targeting Chronic Inflammation

Celldex Therapeutics began Phase 1a study of CDX-622, targeting chronic inflammation through a bispecific antibody approach.Quiver AI SummaryCelldex Therapeutics, Inc. has announced the commencement of...

CLDX : 18.94 (+3.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

3rd Resistance Point 20.81
2nd Resistance Point 20.05
1st Resistance Point 19.50
Last Price 18.94
1st Support Level 18.19
2nd Support Level 17.43
3rd Support Level 16.88

See More

52-Week High 47.00
Fibonacci 61.8% 34.55
Fibonacci 50% 30.70
Fibonacci 38.2% 26.85
Last Price 18.94
52-Week Low 14.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro